Mediwound Ltd (MDWD) was Initiated by Wells Fargo to “Outperform”. Wells Fargo advised their investors in a research report released on Aug 17, 2016.
On the company’s financial health, Mediwound Ltd reported $-0.34 EPS for the quarter, missing the analyst consensus estimate by $ -0.11 based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus of $-0.23. The company had revenue of $.36 million for the quarter, compared to analysts expectations of $.45 million. The company’s revenue was up 115.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.19 EPS.
Mediwound Ltd closed down -0.06 points or -0.88% at $6.74 with 36,749 shares getting traded on Monday. Post opening the session at $6.701, the shares hit an intraday low of $6.7 and an intraday high of $6.9799 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
MediWound Ltd. is a fully integrated biopharmaceutical company. The Company is focused on developing manufacturing and commercializing products to address unmet needs in the fields of severe burns chronic and other hard-to-heal wounds and connective tissue disorders. The Companys biopharmaceutical product NexoBrid which is based on its patented proteolytic enzyme technology represents a new paradigm in burn care management and its clinical trials have demonstrated with statistical significance its ability to non-surgically and rapidly remove the eschar earlier upon patient admission without harming viable tissues. The Company launched NexoBrid in December 2013 in the European Union through its wholly-owned German subsidiary targeting a focused audience of burn specialists treating patients in burn centers and hospital burn units.